Immunologist specialized in immunotherapies and vaccinology, Mathieu Epardaud joined the BioMAP team of UMR ISP 1282 University – INRAE in 2018 to contribute to the development of anti-cancer immunotherapies and develop strategies for mucosal vaccine platforms.
He previously contributed to research on (1) preclinical model for studying the immunopathology of tuberculosis in the same UMR, (2) cancer immunotherapy at the Dana Farber Cancer Institute & Harvard Medical School (Boston) and ( 3) systemic vs mucosal immune response at the INRAe (Jouy en Josas).
Mathieu Epardaud participates in the vaccine development project and is one of the founders in January 2022 of the start-up LoValTech, for which he holds a position of scientific consultant, in particular for the development of the intranasal delivery system.
Experience
-
–presentResearch associate, Inrae
- Tours
- Article Feed
- ORCID
- Joined
